This article is rated C-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects:

Medicine: Hematology-oncology Low‑importance This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles Low This article has been rated as Low-importance on the project's importance scale. This article is supported by the Hematology-oncology task force. Pharmacology Low‑importance This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles Low This article has been rated as Low-importance on the project's importance scale.

Pexa-vec ? or would pexastimogene devacirepvec be the INN ? - Rod57 ( talk) 09:35, 10 May 2013 (UTC) reply

You are right, this page will need moving to pexastimogene devacirepvec, can create a redirect to there from Pexa-vec, this would be in-keeping with talimogene laherparepvec. Viraltonic ( talk) 11:12, 10 May 2013 (UTC) reply

 Done - Rod57 ( talk) 18:45, 14 October 2016 (UTC) reply

Article gives status as of Aug 2011 but the phase III trial failed its primary endpoint in 2013 and the company website gives the March 2014 development plan. - Rod57 ( talk) 23:04, 14 November 2014 (UTC) reply

Website also says "A Phase 2b study (TRAVERSE) was also initiated in HCC patients whose disease had progressed on or following treatment with sorafenib or who could not tolerate that treatment. In September 2013, Transgene announced that the TRAVERSE study did not meet its primary endpoint of overall survival in this challenging-to-treat patient population. Therefore, Pexa-Vec will not be further developed as a second-line treatment for HCC but only in the first-line indication." - Rod57 ( talk) 18:55, 14 October 2016 (UTC) reply

The ribonucleotide reductase gene (aka RNR) may also be deleted - implied by Oct2016 ref, but not mentioned by Cripe2015. - Rod57 ( talk) 18:47, 14 October 2016 (UTC) reply